9/26/2022 8:06:42 AM
Seagen And LAVA Therapeutics Announce Worldwide License Agreement To Develop And Commercialize LAVA-1223
9/19/2022 8:05:10 AM
Seagen : TUKYSA -Trastuzumab Combination Granted Priority Review By FDA For HER2-Positive Metastatic Colorectal Cancer
9/12/2022 9:02:23 AM
Astellas Reports Results Of Trial Of PADCEV -KEYTRUDA &PADCEV As Monotherapy In First-Line Advanced Urothelial Cancer
7/28/2022 4:11:05 PM
Seagen Q2 Loss/share $0.73 Vs. Loss $0.47 Year Ago
7/28/2022 4:10:17 PM
Seagen Inc (SGEN) Has Raised Its 2022 Revenue Estimate To $1.710 - $1.795 Bln From $1.665 - $1.745 Bln
7/26/2022 4:22:18 AM
Astellas, Seagen Announce Positive Topline Results For PADCEV With KEYTRUDA For Advanced Urothelial Cancer
6/6/2022 11:05:01 AM
Genmab And Seagen Present Data From Tisotumab Vedotin Clinical Development Program And Addl Cervical Cancer Research